GLP-1s reduce C-reactive protein among adults without diabetes

Incretin-based medications lower high-sensitivity C-reactive protein levels among adults with a range of cardiometabolic conditions, researchers reported at the International Congress on Obesity. “Clinicians should be aware that when prescribing semaglutide (Wegovy, Novo Nordisk) or tirzepatide (Zepbound, Eli Lilly) for weight management, they may also meaningfully reduce their patients’